New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:05 EDTBSX, BAYRYBoston Scientific agrees to acquire Interventional division of Bayer for $415M
Boston Scientific (BSX) has entered into a definitive agreement to acquire the Interventional Division of Bayer AG (BAYRY) for $415M in cash, including fees for transitional services. The company expects to close the transaction in the second half of 2014, subject to customary closing conditions. The acquisition is expected to improve Boston Scientific's access to a number of attractive segments in the peripheral space, including the growing atherectomy and thrombectomy categories. In 2013, Bayer Interventional generated sales of approximately $120M. Upon completion of the transaction, Bayer Interventional will become part of the existing Boston Scientific Peripheral Interventions business. The agreement calls for an up-front payment of $415M. The company currently expects the transaction to be immaterial to adjusted earnings per share in 2014, accretive by approximately 1c in 2015 and increasingly accretive thereafter. On a GAAP earnings per share basis, the company expects the transaction to be slightly dilutive in 2014, immaterial in 2015, and less accretive than on an adjusted earnings per share basis thereafter as a result of acquisition-related net charges and amortization, which will be determined following the closing. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second half of 2014.
News For BSX;BAYRY From The Last 14 Days
Check below for free stories on BSX;BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
07:31 EDTBAYRYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
07:45 EDTBSXCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
September 12, 2014
15:03 EDTBSXSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 8, 2014
07:26 EDTBSXMorgan Stanley to hold a conference
Subscribe for More Information
07:15 EDTBAYRYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.
September 4, 2014
07:22 EDTBAYRYBayer unit aims to invest $1B before FY16 in U.S., Reuters says
Subscribe for More Information
05:37 EDTBAYRYRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 2, 2014
08:07 EDTBSX, BAYRYBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use